Show simple item record

Phage display broadly identifies inhibitor‐reactive regions in von Willebrand factor

dc.contributor.authorYee, Andrew
dc.contributor.authorDai, Manhong
dc.contributor.authorCroteau, Stacy E.
dc.contributor.authorShavit, Jordan A.
dc.contributor.authorPipe, Steven W.
dc.contributor.authorSiemieniak, David
dc.contributor.authorMeng, Fan
dc.contributor.authorGinsburg, David
dc.date.accessioned2021-11-02T00:48:12Z
dc.date.available2022-12-01 20:48:11en
dc.date.available2021-11-02T00:48:12Z
dc.date.issued2021-11
dc.identifier.citationYee, Andrew; Dai, Manhong; Croteau, Stacy E.; Shavit, Jordan A.; Pipe, Steven W.; Siemieniak, David; Meng, Fan; Ginsburg, David (2021). "Phage display broadly identifies inhibitor‐reactive regions in von Willebrand factor." Journal of Thrombosis and Haemostasis (11): 2702-2709.
dc.identifier.issn1538-7933
dc.identifier.issn1538-7836
dc.identifier.urihttps://hdl.handle.net/2027.42/170895
dc.description.abstractBackgroundCorrection of von Willebrand factor (VWF) deficiency with replacement products containing VWF can lead to the development of anti‐VWF alloantibodies (i.e., VWF inhibitors) in patients with severe von Willebrand disease (VWD).ObjectiveLocate inhibitor‐reactive regions within VWF using phage display.MethodsWe screened a phage library displaying random, overlapping fragments covering the full‐length VWF protein sequence for binding to a commercial anti‐VWF antibody or to immunoglobulins from three type 3 VWD patients who developed VWF inhibitors in response to treatment with plasma‐derived VWF. Immunoreactive phage clones were identified and quantified by next‐generation DNA sequencing (NGS).ResultsNext‐generation DNA sequencing markedly increased the number of phages analyzed for locating immunoreactive regions within VWF following a single round of selection and identified regions not recognized in previous reports using standard phage display methods. Extending this approach to characterize VWF inhibitors from three type 3 VWD patients (including two siblings homozygous for the same VWF gene deletion) revealed patterns of immunoreactivity distinct from the commercial antibody and between unrelated patients, though with notable areas of overlap. Alloantibody reactivity against the VWF propeptide is consistent with incomplete removal of the propeptide from plasma‐derived VWF replacement products.ConclusionThese results demonstrate the utility of phage display and NGS to characterize diverse anti‐VWF antibody reactivities.
dc.publisherWiley Periodicals, Inc.
dc.publisherMcGraw‐Hill Education
dc.subject.othervon Willebrand factor
dc.subject.otheranti‐VWF alloantibodies
dc.subject.othernext‐generation DNA sequencing
dc.subject.otherphage display
dc.subject.othervon Willebrand disease
dc.titlePhage display broadly identifies inhibitor‐reactive regions in von Willebrand factor
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelInternal Medicine and Specialties
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/170895/1/jth15460.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/170895/2/jth15460_am.pdf
dc.identifier.doi10.1111/jth.15460
dc.identifier.sourceJournal of Thrombosis and Haemostasis
dc.identifier.citedreferenceKuwabara I, Maruyama H, Kamisue S, Shima M, Yoshioka A, Maruyama IN. Mapping of the minimal domain encoding a conformational epitope by lambda phage surface display: factor VIII inhibitor antibodies from haemophilia A patients. J Immunol Methods. 1999; 224: 89 ‐ 99.
dc.identifier.citedreferenceVan Blarcom T, Rossi A, Foletti D, Sundar P, et al. Precise and efficient antibody epitope determination through library design, yeast display and next‐generation sequencing. J Mol Biol. 2015; 427 ( 6 ): 1513 ‐ 1534.
dc.identifier.citedreferenceYee A, Gildersleeve RD, Gu S, et al. A von Willebrand factor fragment containing the D’D3 domains is sufficient to stabilize coagulation factor VIII in mice. Blood. 2014; 124: 445 ‐ 452.
dc.identifier.citedreferenceYee A, Kretz CA. Von Willebrand factor: form for function. Semin Thromb Hemost. 2014; 40: 17 ‐ 27.
dc.identifier.citedreferenceJohnsen JM, Ginsburg D. VON Willebrand disease. In: Kaushansky K, Prchal JT, Burns LJ, Lichtman MA, Levi M, Linch DC, eds. Williams hematology, 10e. New York, NY: McGraw‐Hill Education; 2021.
dc.identifier.citedreferenceConnell NT, Flood VH, Brignardello‐Petersen R, et al. ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease. Blood Adv. 2021; 5: 301 ‐ 325.
dc.identifier.citedreferenceJames PD, Lillicrap D, Mannucci PM. Alloantibodies in von Willebrand disease. Blood. 2013; 122: 636 ‐ 640.
dc.identifier.citedreferenceBaaij M, van Galen KPM, Urbanus RT, Nigten J, Eikenboom JHC, Schutgens REG. First report of inhibitory von Willebrand factor alloantibodies in type 2B von Willebrand disease. Br J Haematol. 2015; 171: 424 ‐ 427.
dc.identifier.citedreferenceEhrenforth S, Kreuz W, Scharrer I, et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet. 1992; 339: 594 ‐ 598.
dc.identifier.citedreferencePeyvandi F, Mannucci PM, Garagiola I, et al. A randomized trial of factor VIII and neutralizing antibodies in hemophilia A. N Engl J Med. 2016; 374: 2054 ‐ 2064.
dc.identifier.citedreferenceSpringer TA. von Willebrand factor, Jedi knight of the bloodstream. Blood. 2014; 124: 1412 ‐ 1425.
dc.identifier.citedreferenceLopez‐Fernandez MF, Martin R, Lopez‐Berges C, Ramos F, Bosch N, Batlle J. Further specificity characterization of von Willebrand factor inhibitors developed in two patients with severe von Willebrand disease. Blood. 1988; 72: 116 ‐ 120.
dc.identifier.citedreferenceShibata M, Shima M, Fujimura Y, et al. Identification of the binding site for an alloantibody to von Willebrand factor which inhibits binding to glycoprotein Ib within the amino‐terminal region flanking the A1 domain. Thromb Haemost. 1999; 81: 793 ‐ 798.
dc.identifier.citedreferenceTout H, Obert B, Houllier A, et al. Mapping and functional studies of two alloantibodies developed in patients with type 3 von Willebrand disease. Thromb Haemost. 2000; 83: 274 ‐ 281.
dc.identifier.citedreferenceMohri H, Yamazaki E, Suzuki Z, Takano T, Yokota S, Okubo T. Autoantibody selectively inhibits binding of von Willebrand factor to glycoprotein ib. Recognition site is located in the A1 loop of von Willebrand factor. Thromb Haemost. 1997; 77: 760 ‐ 766.
dc.identifier.citedreferenceSmith GP. Phage display: simple evolution in a petri dish (Nobel Lecture). Angew Chem Int Ed Engl. 2019; 58: 14428 ‐ 14437.
dc.identifier.citedreferenceBahou WF, Ginsburg D, Sikkink R, Litwiller R, Fass DN. A monoclonal antibody to von Willebrand factor (vWF) inhibits factor VIII binding. Localization of its antigenic determinant to a nonadecapeptide at the amino terminus of the mature vWF polypeptide. J Clin Invest. 1989; 84: 56 ‐ 61.
dc.identifier.citedreferenceTan FL, Ginsburg D. What a polyclonal antibody sees in von Willebrand factor. Thromb Res. 2008; 121 ( 4 ): 519 ‐ 526.
dc.identifier.citedreferenceHuang W, Soeung V, Boragine DM, et al. High‐resolution mapping of human norovirus antigens via genomic phage display library selections and deep sequencing. J Virol. 2020; 95 ( 1 ): e01495‐20
dc.identifier.citedreferenceKretz CA, Dai M, Soylemez O, et al. Massively parallel enzyme kinetics reveals the substrate recognition landscape of the metalloprotease ADAMTS13. Proc Natl Acad Sci USA. 2015; 112 ( 30 ): 9328 ‐ 9333.
dc.identifier.citedreferenceYee A, Tan FL, Ginsburg D. Functional display of platelet‐binding VWF fragments on filamentous bacteriophage. PLoS One. 2013; 8: e73518.
dc.identifier.citedreferenceMohlke KL, Purkayastha AA, Westrick RJ, et al. Mvwf, a dominant modifier of murine von Willebrand factor, results from altered lineage‐specific expression of a glycosyltransferase. Cell. 1999; 96: 111 ‐ 120.
dc.identifier.citedreferenceBerntorp E, Agren A, Aledort L, et al. Fifth Aland Island conference on von Willebrand disease. Haemophilia. 2018; 24 ( Suppl 4 ): 5 ‐ 19.
dc.identifier.citedreferenceWeyand AC, Flood VH, Shavit JA, Pipe SW. Efficacy of emicizumab in a pediatric patient with type 3 von Willebrand disease and alloantibodies. Blood Adv. 2019; 3: 2748 ‐ 2750.
dc.identifier.citedreferenceSambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1989.
dc.identifier.citedreferenceLove MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA‐seq data with DESeq2. Genome Biol. 2014; 15: 550.
dc.identifier.citedreferenceDako. Polyclonal rabbit anti‐human von Willebrand factor code A0082. https://www.agilent.com/cs/library/packageinsert/public/SSA0082IVD‐US_01.pdf. Accessed December 29, 2020.
dc.identifier.citedreferenceMohl A, Boda Z, Jager R, et al. Common large partial VWF gene deletion does not cause alloantibody formation in the Hungarian type 3 von Willebrand disease population. J Thromb Haemost. 2011; 9: 945 ‐ 952.
dc.identifier.citedreferenceFaganel Kotnik B, Strandberg K, Debeljak M, et al. von Willebrand factor alloantibodies in type 3 von Willebrand disease. Blood Coagul Fibrinolysis. 2020; 31: 77 ‐ 79.
dc.identifier.citedreferenceHuang CC, Shen MC, Chen JY, Hung MH, Hsu TC, Lin SW. Epitope mapping of factor VIII inhibitor antibodies of Chinese origin. Br J Haematol. 2001; 113: 915 ‐ 924.
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.